Dr Reddys Minoxidil gets CDSCO panel nod to treat androgenic alopecia in females

In the 1970s, minoxidil was launched as an oral drug to treat severe and resistant hypertension. It is an orally administered vasodilator with hair growth stimulatory and antihypertensive effects.

Minoxidil is converted into its active metabolite minoxidil sulphate by sulphotransferase enzymes. Minoxidil sulphate exerts its antihypertensive effect by opening plasma membrane adenosine triphosphate (ATP)-sensitive potassium channels (KATP channels), thereby directly and rapidly relaxing arteriolar smooth muscle and subsequent reduction of elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance.

Minoxidil's hair growth stimulatory effect may be mediated through its vasodilatory activity, thereby increasing cutaneous blood flow, or due to its direct stimulatory effect on hair follicle cells and forcing them from their resting phase into their active growth phase.

Some popular brands of Minoxidil include Sun Pharma's Exidil 5% Solution 60ml, Amexidil-5 Solution 60ml, Dr. Reddy's Mintop Forte 5% Foam 60gm, CIPLA's Tugain 5% Gel 60gm etc.

At the 60th SEC meeting for Dermatology & Allergy held on 12.08.2021, the committee thoroughly reviewed the proposal presented by Dr. Reddy's laboratories for manufacturing and marketing of Minoxidil Topical Solution 2% & 5% for the treatment of androgenic alopecia in females with female pattern baldness with a request for a Clinical Trial waiver.

After detailed deliberation, the committee recommended the grant of permission for the manufacturing and marketing of Minoxidil Topical Solution 2% & 5% for the treatment of androgenic alopecia in females (female pattern hair loss).